Trust leads clinical trial of pioneering product to tackle threatened miscarriage 8 April 2025 Experts from University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are to lead a clinical trial of a novel device aimed at addressing threatened miscarriage. More than 150,000 women a year in the UK could be helped by Callavid® which is designed …
Our colleague Elham Shirani will be at the second Microbes in Women’s Health Congress in Amsterdam on 9-10 April. 🇳🇱 We’re excited to meet with existing and new partners for 2 days of talks, panels and networking. Our user convenient Callavid® drug delivery platform will help provide effective colonisation and epithelial adherence of live biotherapeutics …
[From NIHR: National Institute for Health and Care Research] We have awarded £1 million in funding to a first of its kind technology that’s being trialled to address threatened miscarriage. Currently, over 150,000 women in the UK experience threatened miscarriage a year. If approved, the device would become the world’s first drug-device combination to treat …
🎉 Congratulations to our colleague Sabrina Franco for completing the London Landmarks Half Marathon in support of Tommy’s – the pregnancy and baby charity! We’re proud to support Sabrina’s great work and efforts in raising awareness and funds for such an important cause. 💙
Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials • Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials • Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each …
A slightly belated nod to International Women’s Day (as we’ve just taken this 📸 )— but still just in time for Women’s History Month. I want to take a moment to share how incredibly grateful I am to work alongside such a brilliant, dedicated, and inspiring group of women at Calla Lily Clinical Care 🔬 It’s …
☀️ The sun was shining on Manchester (apparently an unusual phenomenon) yesterday for the very first Fem Health Integrates conference. So many bright minds reunited to discuss the gaps and missed opportunities in women’s health, but mostly the future steps to change the story. 🚺 Thank you to Anastassia Bolotkova for showing me around, Jessica …
The first day of the LSI Emerging Medtech conference in Dana Point, CA was superb – capped off by our well-received presentation on our Callavid® vaginal drug delivery platform. 💪 No doubt buoyed by the momentum surrounding opportunities in women’s health – there was a real buzz leading up to and following our presentation. We’re …
We’ve achieved some exciting IP milestones for Calla Lily Clinical Care; making strong progress in building a robust IP strategy and IP portfolio to protect and advance our innovations in women’s health. 💥 China Patent Grant for our Drug Delivery Device 🌏 At long last, one of our vaginal drug delivery applications in China has …
We’re delighted to be heading to Dana Point, CA during the LSI conference! From March 17th-21st, we’ll be ready to connect, collaborate, and showcase our Callavid® vaginal drug delivery innovation at one of medtech’s premier partnering events. This is an exciting opportunity to discuss new trends, potential collaborations, and meet with valued partners and industry …